With the recent advent of burosumab, the first disease-modifying therapy approved to treat XLH by inhibiting FGF23 to restore phosphate homeostasis, efforts to improve the early diagnosis of patients with XLH are needed [12]. This evidence concerns the gene FGF23 and X-linked hypophosphatemia.